Compare SOTK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | UNCY |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1M | 150.1M |
| IPO Year | 1995 | 2021 |
| Metric | SOTK | UNCY |
|---|---|---|
| Price | $5.32 | $3.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.50 | ★ $28.40 |
| AVG Volume (30 Days) | 134.4K | ★ 859.1K |
| Earning Date | 10-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $20,909,315.00 | $675,000.00 |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $23.41 | $10,812.60 |
| P/E Ratio | $77.71 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.40 | $3.35 |
| 52 Week High | $7.48 | $8.74 |
| Indicator | SOTK | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 27.32 |
| Support Level | $4.07 | N/A |
| Resistance Level | $5.81 | $5.86 |
| Average True Range (ATR) | 0.70 | 0.19 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 8.52 | 13.83 |
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.